-
公开(公告)号：USRE50178E1
公开(公告)日：2024-10-22
申请号：US17464970
申请日：2021-09-02
Applicant: UCB Biopharma SRL
Inventor： John Robert Adair , Diljeet Singh Athwal , John Spencer Emtage
CPC classification number: C07K16/18 , C07K14/461 , C07K16/241 , C07K16/2803 , C07K16/2809 , C07K16/2812 , C07K16/461 , C07K16/465 , A61K38/00 , C07K2317/24 , C07K2317/64 , C07K2319/00
Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
-
公开(公告)号：US20240343802A1
公开(公告)日：2024-10-17
申请号：US18612960
申请日：2024-03-21
Applicant: ZYMEWORKS BC INC.
Inventor： Gordon Yiu Kon Ng , Surjit Bhimarao Dixit , Thomas Spreter von Kreudenstein , Nina E. Weisser
CPC classification number: C07K16/2809 , C07K16/2803 , C07K16/2887 , C07K16/32 , C07K2317/31 , C07K2317/35 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/528 , C07K2317/622 , C07K2317/64 , C07K2317/71 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/92 , C07K2317/94 , C07K2319/31
Abstract: Disclosed herein are isolated multi-specific heteromultimer constructs that bind to CD3 expressed on T-cells and to an antigen expressed on B-cells. The multi-specific heteromultimer constructs are capable of bridging T- and B-cells and mediating killing of B-cells. The multi-specific heteromultimer constructs are based on a heterodimeric Fc scaffold or on a segmented albumin scaffold. Also disclosed herein are multi-specific heteromultimer constructs that bind to HER2 and HER3.
-
3.发明公开
公开(公告)号：US20240343790A1
公开(公告)日：2024-10-17
申请号：US18627131
申请日：2024-04-04
Applicant: Genzyme Corporation
Inventor： Huawei Qiu , Clark Pan , Julie Bird
CPC classification number: C07K16/22 , A61K39/395 , A61K39/3955 , C07K16/00 , C07K16/46 , C12N15/11 , C12N15/62 , A61K2039/505 , C07K2317/21 , C07K2317/35 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/64 , C07K2317/70 , C07K2317/72 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/23 , C07K2319/73
Abstract: An scFv-Fc dimer binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGFβ1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
-
公开(公告)号：US20240327785A1
公开(公告)日：2024-10-03
申请号：US18543857
申请日：2023-12-18
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Lynn Macdonald , Sean Stevens , Cagan Gurer , Andrew J. Murphy , Karolina A. Meagher
IPC: C12N5/0735 , A01K67/0275 , A01K67/0278 , C07K16/00 , C07K16/18 , C07K16/46 , C12N15/10 , C12N15/85
CPC classification number: C12N5/0606 , A01K67/0275 , A01K67/0278 , C07K16/00 , C07K16/18 , C07K16/461 , C07K16/462 , C12N15/10 , C12N15/8509 , A01K2207/15 , A01K2217/05 , A01K2217/052 , A01K2217/072 , A01K2217/15 , A01K2227/105 , A01K2267/01 , A01K2267/02 , A01K2267/0381 , C07K2317/10 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/50 , C07K2317/515 , C07K2317/56 , C07K2317/64
Abstract: Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice that express hVλ sequences from a transgene or an episome wherein the hVλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human λ variable sequences, including human antibodies, are provided.
-
公开(公告)号：US20240309076A1
公开(公告)日：2024-09-19
申请号：US18259734
申请日：2021-12-29
Applicant: REGENXBIO INC. , NEURIMMUNE AG
Inventor： Danielle Sliter , Joseph Bruder , Devin McDougald , Fabio Montrasio , Jan Grimm , Chunping Qiao
CPC classification number: C07K16/18 , A61P25/28 , C12N15/86 , A61K2039/505 , C07K2317/34 , C07K2317/522 , C07K2317/565 , C07K2317/622 , C07K2317/64 , C07K2319/02 , C12N2750/14143
Abstract: The present invention relates to nucleic acid expression cassettes that are engineered to express Tau-specific antibodies. Vectors and methods of employing the expression cassettes containing novel Tau-specific antibodies are provided. The invention is particularly useful for delivery of transgenes to target CNS cells and confers desirable properties for CNS-directed gene therapy. Moreover, the invention relates to a novel method of engineering, and expressing Tau-specific antibody transgenes for example within CNS cells, and delivery of therapeutics for treating various tauopathic diseases and disorders.
-
6.发明公开
公开(公告)号：US20240294899A1
公开(公告)日：2024-09-05
申请号：US18432527
申请日：2024-02-05
Applicant: Iontas Limited
Inventor： John MCCAFFERTY , Michael DYSON , Kothai PARTHIBAN
CPC classification number: C12N15/102 , C07K16/005 , C12N15/1037 , C12N15/907 , C07K2317/24 , C07K2317/622 , C07K2317/64 , C07K2319/03 , C07K2319/035 , C07K2319/036 , C12N2310/20 , C12N2800/30 , C12N2800/80
Abstract: The invention relates to methods of producing eukaryotic cell libraries encoding a repertoire of binding molecules (“binders”), wherein the methods use a site-specific nuclease for targeted cleavage of cellular DNA to enhance site-specific integration of binder genes through endogenous cellular repair mechanisms. Populations of eukaryotic cells are produced in which a repertoire of genes encoding binders are integrated into a desired locus in cellular DNA (e.g., a genomic locus) allowing expression of the encoded binding molecule, thereby creating a population of cells expressing different binders.
-
公开(公告)号：US20240218060A1
公开(公告)日：2024-07-04
申请号：US18220623
申请日：2023-07-11
Applicant: Hoffmann-La Roche Inc.
Inventor： Tillman Schlothauer
CPC classification number: C07K16/22 , A61K2039/505 , C07K2317/31 , C07K2317/33 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/64 , C07K2317/92 , C07K2317/94
Abstract: Herein is reported a polypeptide comprising a first polypeptide and a second polypeptide each comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, wherein
i) the first and the second polypeptide comprise the mutations H310A, H433A and Y436A, or
ii) the first and the second polypeptide comprise the mutations L251D, L314D and L432D, or
iii) the first and the second polypeptide comprise the mutations L251S, L314S and L432S.
-
公开(公告)号：US12018088B2
公开(公告)日：2024-06-25
申请号：US17119073
申请日：2020-12-11
Applicant: University Medical Center Hamburg-Eppendorf
Inventor： Friedrich Nolte , Peter Bannas , Kerstin Schütze , William Fumey , Levin Schriewer , Stephan Menzel , Catelijne Stortelers
CPC classification number: C07K16/2896 , A61P37/06 , C12N15/86 , C12Q1/25 , G01N33/53 , A61K2039/505 , C07K2317/22 , C07K2317/31 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2317/75 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to polypeptides specifically binding to CD38 and are therefore suitable for the diagnosis and for the therapeutic and prophylactic treatment of diseases which are characterized by increased CD38 expression. Conjugates and pharmaceutical compositions comprising the polypeptides are disclosed as well. In addition, the invention relates to the use of such polypeptides in methods for the detection of CD38 and/or CD38-expressing cells in a biological sample. A process for the purification and concentration of CD38 and/or CD38-expressing cells in which the antigen-binding polypeptides are used are also described.
-
公开(公告)号：US11952421B2
公开(公告)日：2024-04-09
申请号：US15517296
申请日：2015-10-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Minh Diem Vu , Klaus Strein , Oliver Ast , Tanja Fauti , Anne Freimoser-Grundschober , Ralf Hosse , Christian Klein , Ekkehard Moessner , Samuel Moser , Ramona Murr , Pablo Umana , Sabine Jung-Imhof , Stefan Klostermann , Michael Molhoj , Joerg Regula , Wolfgang Schaefer
CPC classification number: C07K16/2809 , C07K16/2803 , A61K2039/505 , C07K2317/31 , C07K2317/64 , C07K2317/73 , C07K2317/77
Abstract: The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.
-
10.发明公开
公开(公告)号：US20240026002A1
公开(公告)日：2024-01-25
申请号：US18452395
申请日：2023-08-18
Applicant: Xencor, Inc.
Inventor： Matthew J. Bernett , Gregory Moore , John Desjarlais , Michael Hedvat , Christine Bonzon
CPC classification number: C07K16/2818 , A61P35/00 , A61P37/06 , C07K16/2803 , C07K16/2827 , C07K2317/55 , C07K2317/622 , C07K2317/64 , C07K2317/76 , C07K2317/52 , C07K2317/33 , C07K2317/31 , A61K2039/507
Abstract: The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.
